Comparison

Tizanidine European Partner

Item no. HY-B0194-1ea
Manufacturer MedChem Express
CASRN 51322-75-9
Amount 1 ea
Quantity options 100 mg 10 mg 1 ea 50 mg 5 mg
Category
Type Chemicals
Specific against other
Purity 99.58
Citations [1]Kamen L, et al. A practical overview of tizanidine use for spasticity secondary to multiple sclerosis, stroke, and spinal cord injury. Curr Med Res Opin. 2008 Feb;24(2):425-39.
Smiles ClC1=C(NC2=NCCN2)C3=NSN=C3C=C1
ECLASS 10.1 32160000
ECLASS 11.0 32160000
UNSPSC 12000000
Shipping Condition Room temperature
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
Metabolism-protein/nucleotide metabolism
Manufacturer - Targets
Adrenergic Receptor
Shipping Temperature
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Molecular Weight
253.71
Product Description
Tizanidine is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.Target: α2-adrenergic receptorTizanidine is a drug that is used as a muscle relaxant. It is a centrally acting α2 adrenergic agonist. It is used to treat the spasms, cramping, and tightness of muscles caused by medical problems such as multiple sclerosis, ALS, spastic diplegia, back pain, or certain other injuries to the spine or central nervous system. It is also prescribed off-label for migraine headaches, as a sleep aid, and as an anticonvulsant. It is also prescribed for some symptoms of fibromyalgia.Tizanidine has been found to be as effective as other antispasmodic drugs and has superior tolerability to that of baclofen and diazepam. Tizanidine can be very strong even at the 2 mg dose and may cause hypotension, so caution is advised when it is used in patients who have a history of orthostatic hypotension, or when switching from gel cap to tablet form and vice versa. Tizanidine can occasionally cause liver damage, generally the hepatocellular type. Clinical trials show that up to 5% of patients treated with tizanidine had elevated liver function test values, though symptoms disappeared upon withdrawal of the drug. Care should be used when first beginning treatment with tizanidine with regular liver tests for the first 6 months of treatment.
Manufacturer - Research Area
Neurological Disease; Endocrinology; Cancer
Solubility
DMSO: 22.22 mg/mL (ultrasonic; adjust pH to 3 with 1M HCl)
Manufacturer - Pathway
GPCR/G Protein; Neuronal Signaling
Isoform
α adrenergic receptor
Clinical information
Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 ea
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close